A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma

Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin wer...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cell reports. Medicine Ročník 6; číslo 6; s. 102165
Hlavní autori:	Lopez, Juanita Suzanne, Haefliger, Simon, Plummer, Ruth, Clement, Paul M., Jeffry Evans, Thomas R., Läubli, Heinz, Roth, Patrick, Kristeleit, Rebecca, Brazil, Lucy, Tabatabai, Ghazaleh, Wick, Antje, Wunderlich, Benjamin, Beebe, Kirk, Eisner, Joel Robert, Lane, Heidi, Engelhardt, Marc, Kaindl, Thomas, Hau, Peter, Hundsberger, Thomas, Steinbach, Joachim
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 17.06.2025 Elsevier
Predmet:	Administration, Oral Adult Advanced Basic Science Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use astrocytoma Biomarkers, Tumor - metabolism Brain Neoplasms - drug therapy Brain Neoplasms - pathology Dose-Response Relationship, Drug Female glioblastoma Glioblastoma - drug therapy Glioblastoma - metabolism Glioblastoma - pathology glioma Glioma - drug therapy Glioma - metabolism Glioma - pathology Humans lisavanbulin Male Middle Aged Neoplasm Grading glioma glioblastoma lisavanbulin astrocytoma
ISSN:	2666-3791, 2666-3791
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!